Emergent BioSolutions (EBS) Tops Q4 EPS by 46c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.37 +2.83%
Revenue Growth %: +32.0%
Financial Fact:
Interest income: 358K
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +32.0%
Financial Fact:
Interest income: 358K
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.05, $0.46 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $194.7 million versus the consensus estimate of $243.33 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI's Altman: rise in cost of compute and memory definitely a headwind - CNBC Interview
- Karbon-X opens EU carbon registry account in Spain
- Meta launches first paid AI developer model with new API - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
